Assessing the potential cost-effectiveness of retesting IHC0, IHC1-positive, or FISH-negative early-stage breast cancer patients for HER2 status

被引：1
|
作者：
Garrison, L. P.
Lalla, D.
Brammer, M. G.
Wang, B.
Babigumira, J.
Perez, E. A.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] Mayo Clin, Jacksonville, FL 32224 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.6133
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6133
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Change in HER2 status after neoadjuvant chemotherapy (NAC) with trastuzumab and pertuzumab (HP) in patients with HER2-positive early-stage breast cancer.
    Ferraro, Emanuela
    Razavi, Pedram
    Chandarlapaty, Sarat
    Modi, Shanu
    Wen, Hannah Yong
    Brogi, Edi
    Norton, Larry
    Robson, Mark E.
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer
    Sussell, Jesse A.
    Roth, Joshua A.
    Meyer, Craig S.
    Fung, Anita
    Hansen, Svenn A.
    ADVANCES IN THERAPY, 2022, 39 (03) : 1375 - 1392
  • [33] Cost-effectiveness analysis of trastuzumab therapy in patients with early HER-2 positive breast cancer in Brazil
    Vernaglia, P. R.
    Cunha, F. M.
    Correa, M.
    Perdicaris, M. R.
    Saggia, M. G.
    Santos, E. A., V
    Nasciben, V. D.
    Pelizon, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S106 - S106
  • [34] Prognosis prediction with the IHC3 score in patients with node-negative, hormone receptor-positive, HER2-negative early breast cancer
    Seitz, K.
    Goossens, C.
    Huebner, H.
    Gass, P.
    Uhrig, S.
    Heindl, F.
    Emons, J.
    Ruebner, M.
    Anetsberger, D.
    Hartmann, A.
    Beckmann, M. W.
    Erber, R.
    Hack, C. C.
    Fasching, P. A.
    Haeberle, L.
    ESMO OPEN, 2024, 9 (11)
  • [35] Cost-effectiveness of one-year adjuvant trastuzumab therapy in treatment for early-stage breast cancer patients with HER2+in Vietnam
    Nguyen, Anh Quynh
    Tran, Oanh Thi Mai
    Nguyen, Phuong Khanh
    Nguyen, Ha Thu
    PLOS ONE, 2024, 19 (03):
  • [36] Comparison of the cost-effectiveness of multigene assays for HR+/HER2-nodenegative early-stage breast cancer in the US
    Berdunov, Vladislav
    Carter, Gebra Cuyun
    Russell, Christy
    Campbell, Sara
    Racz, Jennifer
    Abdou, Yara
    CANCER RESEARCH, 2024, 84 (09)
  • [37] Correction to: Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer
    Jesse A. Sussell
    Joshua A. Roth
    Craig S. Meyer
    Anita Fung
    Svenn A. Hansen
    Advances in Therapy, 2022, 39 : 3423 - 3423
  • [38] The effect of trastuzumab (Herceptin®) treatment on estrogen receptor status in patients with early stage HER2 positive breast cancer
    Witkiewicz, AK
    Pliss, N
    Kamma, M
    Schnitt, S
    Burstein, HJ
    Harris, L
    LABORATORY INVESTIGATION, 2005, 85 : 55A - 55A
  • [39] The effect of trastuzumab (Herceptin®) treatment on estrogen receptor status in patients with early stage HER2 positive breast cancer
    Witkiewicz, AK
    Pliss, N
    Kamma, M
    Schnitt, S
    Burstein, HJ
    Harris, L
    MODERN PATHOLOGY, 2005, 18 : 55A - 55A
  • [40] Cost-Effectiveness Analysis from a Societal Perspective of Recurrence Index for Distant Recurrence (Recurindex) in Women with Hormone Receptor-Positive and HER2-Negative Early-Stage Breast Cancer
    Pennarun, Nicolas
    Chiu, Jian-Ying
    Chang, Hsun-Chen
    Huang, Sean-Lin
    Cheng, Skye Hung-Chun
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 761 - 773
12345